ANTI-CANCER DRUGS

Scope & Guideline

Leading the Charge in Cancer Drug Development

Introduction

Welcome to your portal for understanding ANTI-CANCER DRUGS, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0959-4973
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1990 to 2024
AbbreviationANTI-CANCER DRUG / Anti-Cancer Drugs
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal "ANTI-CANCER DRUGS" is dedicated to the dissemination of significant research findings in the field of oncology, particularly focusing on the development and evaluation of new therapeutic agents and strategies for cancer treatment. The journal emphasizes innovative approaches to drug development, efficacy, safety, and the biological mechanisms of action of anti-cancer therapies.
  1. Novel Drug Development:
    The journal covers research on new anti-cancer agents, including small molecules, biologics, and combination therapies, focusing on their mechanisms of action, pharmacodynamics, and pharmacokinetics.
  2. Clinical Trials and Case Reports:
    It publishes results from clinical trials, including phase I-III studies, as well as detailed case reports that highlight unique therapeutic responses or adverse events associated with anti-cancer drugs.
  3. Biomarkers and Personalized Medicine:
    The journal emphasizes the identification and validation of biomarkers that can predict treatment responses, guiding personalized therapy and improving patient outcomes.
  4. Mechanistic Studies:
    It includes studies that elucidate the molecular, cellular, and genetic mechanisms underlying cancer progression and drug resistance, contributing to a deeper understanding of cancer biology.
  5. Therapeutic Strategies and Combinations:
    The journal focuses on innovative therapeutic strategies, including combination therapies, immunotherapies, and targeted therapies, to overcome resistance and enhance treatment efficacy.
The journal "ANTI-CANCER DRUGS" reflects the dynamic nature of cancer research, with several emerging themes gaining prominence in recent publications. These trends indicate a shift towards more personalized and targeted approaches to cancer treatment.
  1. Immunotherapy and Checkpoint Inhibitors:
    There is a significant increase in studies examining the efficacy and safety of immunotherapies, including checkpoint inhibitors, indicating a trend towards harnessing the immune system in cancer treatment.
  2. Targeted Therapy Innovations:
    Emerging research on novel targeted therapies, particularly those addressing specific genetic mutations (e.g., EGFR, ALK), is on the rise, highlighting the importance of precision medicine in oncology.
  3. Combination Therapies:
    An increasing number of studies are exploring combination therapies that integrate traditional chemotherapy with targeted agents or immunotherapies, reflecting a trend towards multi-faceted treatment approaches.
  4. Research on Drug Resistance Mechanisms:
    There is a growing focus on understanding the mechanisms of drug resistance, particularly in relation to targeted therapies and immunotherapies, which is crucial for improving patient outcomes.
  5. Biomarker-Driven Treatment Approaches:
    The trend towards biomarker-driven treatment strategies is evident, with an emphasis on personalized medicine that tailors therapies based on individual patient profiles and tumor characteristics.

Declining or Waning

Despite the journal's comprehensive focus on the evolving landscape of cancer therapeutics, certain themes appear to be waning or receiving less emphasis in recent publications. These declining areas may reflect shifts in research priorities or emerging challenges in oncology.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in research focused solely on traditional chemotherapy agents without the integration of novel therapeutic strategies or combinations, as the field shifts towards targeted and personalized medicine.
  2. Monotherapy Studies:
    Publications centered around monotherapy approaches are becoming less frequent, with a growing emphasis on combination therapies that leverage synergies between different modalities to enhance efficacy.
  3. Exploratory Preclinical Studies:
    The journal has seen a reduction in the publication of exploratory preclinical studies that do not have a clear translational pathway to clinical application, as there is a stronger focus on studies that directly inform clinical practice.
  4. General Cancer Epidemiology:
    Research focused on broad epidemiological studies without a direct link to therapeutic interventions or drug efficacy is also waning, as the journal prioritizes studies with actionable insights for treatment.

Similar Journals

CANCER RESEARCH

Advancing the frontiers of oncology research.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

INTERNATIONAL JOURNAL OF ONCOLOGY

Empowering breakthroughs in oncology and patient care.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

BRITISH JOURNAL OF PHARMACOLOGY

Advancing pharmacological science for a healthier tomorrow.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

Journal of Pharmacological Sciences

Innovating drug development through impactful science.
Publisher: JAPANESE PHARMACOLOGICAL SOCISSN: 1347-8613Frequency: 12 issues/year

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Transforming research into practice in clinical pharmacology.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Drug Discoveries and Therapeutics

Empowering researchers with cutting-edge insights.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

ACTA PHARMACOLOGICA SINICA

Championing High-Impact Research in Pharmacology
Publisher: NATURE PUBL GROUPISSN: 1671-4083Frequency: 12 issues/year

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

Drug Research

Catalyzing Collaboration in Drug Research
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Drug Target Insights

Illuminating Pathways in Drug Targeting and Development.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Anti-Cancer Agents in Medicinal Chemistry

Uncovering the future of anti-cancer strategies.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.